Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma

Similar Items

• Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High Risk Melanoma
  od: Sabado, Rachel Lubong, i dr.
  Izdano: (2015)
• Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using Toll-like receptor 7 agonist imiquimod as vaccine adjuvant
  od: Adams, Sylvia, i dr.
  Izdano: (2008)
• Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
  od: Hunder, Naomi N., i dr.
  Izdano: (2008)
• Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in high-risk melanoma patients
  od: Pavlick, Anna, i dr.
  Izdano: (2019)
• Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
  od: Jäger, Elke, i dr.
  Izdano: (2000)